Tags

Type your tag names separated by a space and hit enter

Iron overload in nonalcoholic steatohepatitis.
Adv Clin Chem 2011; 55:105-32AC

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major causative agent of chronic liver disease worldwide, but the actual mechanisms responsible for liver injury remain unclear. NAFLD includes a spectrum of clinical entities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with possible evolution to cirrhosis and hepatocellular carcinoma. Iron is considered a putative element that interacts with oxygen radicals in inducing liver damage/fibrosis and insulin resistance. The role of hepatic iron in the progression of NASH remains controversial, but in some patients, iron may have a role in the pathogenesis of NASH. Though genetic factors, insulin resistance, dysregulation of iron-regulatory molecules, erythrophagocytosis by Kupffer cells may be responsible for hepatic iron accumulation in NASH, exact mechanisms involved in iron overload remain to be clarified. Iron reduction therapy such as phlebotomy or iron-restricted diet may be promising in patients with NAFLD/NASH to reduce hepatic injury as well as insulin resistance. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of phlebotomy and/or iron-restricted diet in NAFLD/NASH.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, Division of Clinical Medicine and Biomedical Science, Institute of Medical Sciences, Mie University Graduate School of Medicine, Mie, Japan. nfujita@clin.medic.mie-u.ac.jpNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22126026

Citation

Fujita, Naoki, and Yoshiyuki Takei. "Iron Overload in Nonalcoholic Steatohepatitis." Advances in Clinical Chemistry, vol. 55, 2011, pp. 105-32.
Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-32.
Fujita, N., & Takei, Y. (2011). Iron overload in nonalcoholic steatohepatitis. Advances in Clinical Chemistry, 55, pp. 105-32.
Fujita N, Takei Y. Iron Overload in Nonalcoholic Steatohepatitis. Adv Clin Chem. 2011;55:105-32. PubMed PMID: 22126026.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Iron overload in nonalcoholic steatohepatitis. AU - Fujita,Naoki, AU - Takei,Yoshiyuki, PY - 2011/12/1/entrez PY - 2011/12/1/pubmed PY - 2011/12/23/medline SP - 105 EP - 32 JF - Advances in clinical chemistry JO - Adv Clin Chem VL - 55 N2 - Nonalcoholic fatty liver disease (NAFLD) is a major causative agent of chronic liver disease worldwide, but the actual mechanisms responsible for liver injury remain unclear. NAFLD includes a spectrum of clinical entities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with possible evolution to cirrhosis and hepatocellular carcinoma. Iron is considered a putative element that interacts with oxygen radicals in inducing liver damage/fibrosis and insulin resistance. The role of hepatic iron in the progression of NASH remains controversial, but in some patients, iron may have a role in the pathogenesis of NASH. Though genetic factors, insulin resistance, dysregulation of iron-regulatory molecules, erythrophagocytosis by Kupffer cells may be responsible for hepatic iron accumulation in NASH, exact mechanisms involved in iron overload remain to be clarified. Iron reduction therapy such as phlebotomy or iron-restricted diet may be promising in patients with NAFLD/NASH to reduce hepatic injury as well as insulin resistance. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of phlebotomy and/or iron-restricted diet in NAFLD/NASH. SN - 0065-2423 UR - https://www.unboundmedicine.com/medline/citation/22126026/Iron_overload_in_nonalcoholic_steatohepatitis_ L2 - http://www.diseaseinfosearch.org/result/3874 DB - PRIME DP - Unbound Medicine ER -